• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ADA 2017 Roundup: Photo ban causes stir among conference attendees

June 12, 2017 By Sarah Faulkner

Many scientific conferences have embraced the technological age, creating hashtags for attendees to share content on Twitter and engage with one another. Some conferences even acknowledge attendees with powerful social media presences by giving them special ribbons and including their Twitter handles on their name badges.

But at this year’s meeting of the American Diabetes Association, the conference’s official hashtag was dominated by angry attendees protesting a seemingly old-school policy: attendees were not allowed to post photos from presentations on Twitter.

“The photoban at #ada2017 #2017ada threatens a strong educational movement of open sharing across all medical meetings,” Dr. Neil Floch wrote.

Some pointed out on Twitter that sharing data online is an important resource for doctors who aren’t able to be at the meeting in person and that encouraging communication among attendees could help spur new research ideas.

The ADA’s official policy claimed that by registering for the conference, attendees gave the ADA the perpetual, global and royalty-free right to record, photograph and use anything from the conference. The policy didn’t sit well with many on Twitter.

“#ADA2017 : If you claim your are protecting presenter’s intellectual property why do you state that you alone are free to use it as below,” Dr. C. Michael Gibson tweeted.

Gibson, who has a sizeable online presence, tweeted several times using the conference’s hashtag to express his dissatisfaction with the rule.

Some presenters attempted to circumvent the policy, tweeting that attendees were welcome to take pictures and share their presentations online.

“People come present their data in a public forum because they want to share their research & promote their work, not hide it,” Gibson wrote.

NEXT: Insulet touts Omnipod Horizon glucose control system in kids with Type I diabetes

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Big Data, Clinical Trials, Diabetes, Featured Tagged With: eigerbiopharmaceuticals, Insulet, Mylan, Novo Nordisk, Sanofi-Aventis, Tandem Diabetes Care, University of North Carolina, Valeritas Inc.

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS